HighTower Advisors
VVOS icon

HighTower Advisors’s Vivos Therapeutics VVOS Stock Holding History

HighTower Advisors’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-746
Closed -$4K – 3867
2023
Q3 		$4K Buy
+746
New +$5.63K ﹤0.01% 3436

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HighTower Advisors's VVOS Position: Q4 2023 in Review

HighTower Advisors sold out of Vivos Therapeutics (VVOS) in Q4 2023, closing a stake of 746 shares — an estimated $4K sold.

HighTower Advisors first reported a position in VVOS in Q3 2023 and held it in 1 quarter. The position peaked at $4K in Q3 2023. 18 funds tracked by Wall St. Rank hold VVOS as of Q4 2023.

  • HighTower Advisors reported no remaining Vivos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • HighTower Advisors sold 746 Vivos Therapeutics shares in Q4 2023, an estimated $4K.
  • HighTower Advisors first reported a position in Vivos Therapeutics in Q3 2023 and held it in 1 quarter.
  • HighTower Advisors's Vivos Therapeutics position peaked at $4K in Q3 2023.
  • 18 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2023.

Based on HighTower Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.